Ignacio Baselga-Carretero

PAK4 inhibition improves PD-1 blockade immunotherapy

B. Comin-Anduix, A. Ribas, E. Baloglu, 2019, Nature Cancer.

Neoantigen-targeted CD8^+ T cell responses with PD-1 blockade therapy

O. Griffith, M. Griffith, A. Ribas, 2023, Nature.

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

J. Sosman, A. Ribas, P. Scumpia, 2023, Nature Medicine.

A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer

A. Ribas, J. Glaspy, T. Nowicki, 2023, Cancer research communications.

Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade

Katie M. Campbell, B. Comin-Anduix, A. Ribas, 2022, Cancer research communications.

Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy

B. Comin-Anduix, B. Berent-Maoz, P. Kaplan-Lefko, 2023, Cancer immunology research.